Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healthcare services drive the growth of the global market.
PORTLAND, OR, UNITED STATES, January 29, 2025 /EINPresswire.com/ -- Allied Market Research published a report, titled, "Duchenne Muscular Dystrophy Market by Therapeutic Area, (Molecular-based Therapies and Steroid Therapy), and Distribution Channel (Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2022-2031". Duchenne Muscular Dystrophy (DMD) Market Size was Valued at USD 1.3 billion in 2021 and is Projected to Garner USD 2.1 billion by 2031, registering a CAGR of 4.7% from 2022 to 2031.This report provides a comprehensive overview of the Duchenne Muscular Dystrophy Market, including an in-depth analysis of market trends, key segments, investment opportunities, value chain analysis, regional landscape, and competitive scenarios. It offers valuable insights for established market players, new entrants, investors, and other stakeholders to devise effective strategies and make informed decisions to enhance their market position. The report is a valuable resource for anyone seeking to gain a deeper understanding of the Duchenne Muscular Dystrophy Market and its growth potential in the future.
Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healthcare services drive the growth of the global Duchenne muscular dystrophy market. However, inflated cost of treatments for Duchenne muscular dystrophy restricts the market growth. On the other hand, increase in government spending on the pharmaceutical and biotechnology sectors in developing countries, the development of healthcare infrastructure, and rise in demand for innovative treatments for Duchenne muscular dystrophy present new opportunities in the coming years.
๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐ซ๐๐ฉ๐ก๐ฌ ๐๐ง๐ ๐ ๐ข๐ ๐ฎ๐ซ๐๐ฌ ๐๐๐ซ๐: https://www.alliedmarketresearch.com/request-sample/A15646
๐๐จ๐ฉ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ ๐๐ ๐๐ฎ๐๐ก๐๐ง๐ง๐ ๐๐ฎ๐ฌ๐๐ฎ๐ฅ๐๐ซ ๐๐ฒ๐ฌ๐ญ๐ซ๐จ๐ฉ๐ก๐ฒ (๐๐๐)
โข F Hoffmann-La Roche AG
โข FibroGen, Inc
โข GlaxoSmithKline plc
โข Italfarmaco S.p.A.
โข Nippon Shinyaku Co., Ltd
โข Pfizer Inc.
โข PTC Therapeutics
โข Santhera Pharmaceuticals Inc
โข Sarepta therapeutics
โข Wave life sciences ltd.
โข ABBOTT LABORATORIES
๐๐ฎ๐๐ก๐๐ง๐ง๐ ๐๐ฎ๐ฌ๐๐ฎ๐ฅ๐๐ซ ๐๐ฒ๐ฌ๐ญ๐ซ๐จ๐ฉ๐ก๐ฒ (๐๐๐) ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง: โ
Based on therapeutic area, the molecular-based therapies segment held the highest market share in 2021, accounting for around three-fifths of the global Duchenne muscular dystrophy market, and is estimated to maintain its leadership status throughout the forecast period. In addition, the same segment is projected to manifest the highest CAGR of 5.0% from 2022 to 2031, owing to R & D activities for exon skipping drugs, strong product pipeline and significant product launch by key players. The report also discusses steroid therapy segment.
Based on distribution channel, the hospital pharmacies segment accounted for the largest share in 2021, contributing to more than three-fifths of the global Duchenne muscular dystrophy market, and is projected to maintain its lead position during the forecast period. This is owing to significant rise in the number of diagnosis through hospitals. However, the drug store & retail pharmacies segment is expected to portray the largest CAGR of 5.4% from 2022 to 2031, owing to the rise in the approval of drugs and their availability in drug store & retail pharmacies.
Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than half of the global Duchenne muscular dystrophy market, and is likely to dominate the market during the forecast period. This is owing to technological advancements in Duchenne muscular dystrophy treatment and presence of key players & robust hospital infrastructure in the region.
However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.9% from 2022 to 2031. This is owing to rise in cases of Duchenne muscular dystrophy, approval of drugs, development of healthcare infrastructure, and increase in investments projects in the region.
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐ญ๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/purchase-enquiry/16015
Key Benefits For Stakeholders
โข The report provides an in-depth analysis of the Duchenne muscular dystrophy market size along with the current trends and future estimations to elucidate imminent investment pockets.
โข It offers market analysis from 2022 to 2031, which is expected to enable stakeholders to capitalize on prevailing opportunities in the Duchenne muscular dystrophy market.
โข A comprehensive analysis on region assists to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
โข The profiles and growth strategies of key players are thoroughly analyzed to understand competitive outlook of the global Duchenne muscular dystrophy treatment market growth.
๐๐ฎ๐ซ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง ๐๐ซ๐จ๐ฏ๐ข๐๐๐ฌ ๐๐จ๐ฎ ๐๐ง๐ฌ๐ฐ๐๐ซ ๐ญ๐จ ๐๐๐ฅ๐จ๐ฐ ๐๐๐ง๐ญ๐ข๐จ๐ง๐๐ ๐๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง:
โข Which are the driving factors responsible for the growth of market?
โข Which are the roadblock factors of this market?
โข What are the new opportunities, by which market will grow in coming years?
โข What are the trends of this market?
โข Which are main factors responsible for new product launch?
โข How big is the global & regional market in terms of revenue, sales and production?
โข How far will the market grow in forecast period in terms of revenue, sales and production?
โข Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
โข How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
โข Which region has more opportunities?
๐๐ฒ ๐๐๐ ๐ข๐จ๐ง ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค
โข North America
(U.S., Canada, Mexico)
โข Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
โข Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
โข LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
๐๐จ๐ง๐ญ๐๐๐ญ ๐๐๐ญ๐๐ข๐ฅ๐ฌ:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com
๐๐๐จ๐ฎ๐ญ ๐๐ฌ
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
David Correa
Allied Market Research
+ + +1 800-792-5285
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.